Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672321 | 0.84 | CA1 (0.46) | KDM4EALDH1A1HPGDNPSR1CA1 | |
| SCHEMBL3714158 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDNPSR1MEN1 | |
| SCHEMBL4150121 | 0.83 | CA1 (0.51) | KDM4EALDH1A1HPGDCA1CA2 | |
| SCHEMBL7672154 | 0.81 | CYP1A2 (0.46) | KDM4EALDH1A1HPGDNPSR1MAPT | |
| SCHEMBL756422 | 0.81 | XDH (0.62) | KDM4EALDH1A1HPGDCA1CA2 | |
| SCHEMBL20906102 | 0.80 | XDH (0.74) | XDHSLC22A12MEN1KMT2AMAPT | |
| SCHEMBL26337729 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1HPGDCA1CA2 | |
| SCHEMBL758397 | 0.80 | CA1 (0.56) | KDM4EALDH1A1HPGDCA1CA2 | |
| SCHEMBL5315678 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1HPGDNPSR1CA1 | |
| SCHEMBL15936293 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDNPSR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114408-B1 | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2114408-A1 | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008091631-A1 | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| US-6821973-B2 | ANTAGONIZE THE PHARMACOLOGICAL ACTIONS OF THE ENDOGENOUS NEUROPEPTIDE TACHYKININS KNOWN AS NEUROKININS | ASTRAZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1169302-B1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20040106610-A1 | Compounds | BERNSTEIN PETER ROBERT (US) | 2004-06-03 | — | — | US | disclosed |
| US-6586432-B2 | Peptide neurotransmitter suppressors such as N-((-2-(3,4-dichlorophenyl)-4-morholino)butyl)-N-methyl-2-methoxy-3-cyano-1 -naphthamide, used for prophylaxis of arthritis, pain, alzheimer's disease, schizophrenia, edema, rhinitis or asthma | ASTRAZENELA AB (SE) | 2003-07-01 | — | — | US | disclosed |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | BERNSTEIN PETER ROBERT (US) | 2003-05-15 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106610-A1 | Compounds | NR2C2, NR0B2, NR5A2 | KDM4E 2462/4885ALDH1A1 2538/4885HPGD 3657/4885 |
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GLP1R | KDM4E 3052/4885ALDH1A1 4345/4885HPGD 2553/4885 |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | NTSR2, NTSR1, CRHR2 | KDM4E 2703/4885ALDH1A1 2644/4885HPGD 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.